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Background/aim: High-dose steroid has been shown to reduce the mortality rate in Corona virus disease 2019 (COVID-19) patients who need
oxygen support. Here, we evaluated the effectiveness of pulse-steroid in case of unresponsiveness to treatment with high dose steroid.
Materials and methods: The study is a retrospective controlled trial. We divided the patients in 3 groups: standard-care therapy alone, highdose steroid treatment (6 mg/day dexamethasone equivalent), and pulse-steroid treatment (250 mg/day methyl-prednisolone). One hundred
and fifty patients were enrolled in each group. All patients were hospitalized and needed oxygen support. We matched the patients according
to disease severity at the onset of hypoxia, weight of co-morbidities, age, and sex. We then compared 3 groups in terms of mortality, length of
hospitalization, need for intensive care unit (ICU) admission and mechanical ventilation (MV), length of stay in ICU, and duration of MV.
Results: The pulse-steroid group had shorter ICU stay. The median ICU stay was 9.0 (CI 95% 6.0–12.0) days in standard-care group, 8.0 (CI
95% 5.0–13.0) days in high-dose steroid group and 4.5(CI %95 3.0–8.0) days in pulse-steroid group. Moreover, although patients in pulsesteroid group were initially unresponsive to high dose steroid therapy, they achieved similar results compared to the high-dose steroid group
in other outcomes except for length of hospital stay.
Conclusion: Pulse-steroid treatment would be an option for COVID-19 patients who do not respond to the initial high-dose steroid treatment.
Key words: Coronavirus disease 2019, steroid treatment, mortality rate, intensive care unit stay

1. Introduction
Coronavirus disease 2019 (COVID-19) is a potentially fatal
multisystem disease which is caused by SARS-CoV 2, novel
form of Coronavirus [1]. Many organ systems including
cardiac [2], nervous [3], renal [4], gastrointestinal [5], and
coagulation systems [6] would suffer from the disease.
However, respiratory illnesses that require hospitalization
and oxygen supplement and in critical cases, requirement of
intensive care unit support are the main severe clinical
pictures of the disease [7].
The effectiveness of various re-purposed drugs in
COVID-19 has been studied in the course of the pandemic
[8]. However, there are no proven effective treatment
modalities that cure COVID-19 or reduce the mortality rate
of the disease so far. Remdesivir, a promising antiviral drug,
has recently been shown to shorten the recovery time [9].
Acute pneumonia caused by host immunity, diffuse
alveolar damage, and increased tendency to generalized
micro-thrombosis are the characteristic pathophysiological
features of the disease [10]. Therefore, in special
circumstances, well-timed and appropriate doses of
antiinflammatory drugs would be a promising treatment
option for COVID-19 [11]. Recently, it has been shown that
high dose of the key antiinflammatory drugs, corticosteroids,
reduce 28-day mortality in the COVID-19 patients who need

oxygen supplementation [12]. In addition, several
randomized studies have demonstrated the beneficial effect of
various doses of corticosteroids on 28-day all-cause mortality
from COVID-19 [13]. In these studies, the effect of
corticosteroid treatment was compared with standard care
only.
In our daily medical practice, we observed that some
patients would not respond adequately to the moderate or
high dose steroid treatment within the scope of clinical,
radiologic and laboratory parameters. In these cases, we
speculated that if the high dose steroid treatment fails, add-on
very high dosage or pulse steroid treatment would be a
treatment option to accompany standard therapy.
In this study, we assessed the effect of add-on 250 mg pulse
methyl prednisolone treatment in hypoxic and/or oxygen
requiring hospitalized COVID-19 patients despite the failure
of high dose steroid treatment. We retrospectively included 3
different COVID-19 cohorts here: patients on standard
therapy only, cases on standard therapy plus high dose steroid
treatment, and finally the patients that were administered
add-on pulse steroid, if high dose steroid treatment fails. We
compared these groups for mortality, need for intensive care
unit (ICU) admission or frequency of mechanical ventilation
(MV), length of hospitalization, and duration of stay in the
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ICU, duration of need for MV, and frequency of steroidrelated side effects.
2. Materials and methods
Four hundred fifty individuals with COVID-19 over the age
of 18 were retrospectively enrolled in the study. All patients
were hospitalized in a tertiary health-care facility due to
COVID-19. Additionally, all study participants had hypoxia
and/or needed oxygen support. The COVID-19 patients with
any of corticosteroid contraindications, who were transferred
to ICU or who needed MV prior to target steroid treatment
(in the high steroid dose group before administering any dose
of steroid and in the pulse steroid group before starting pulse
steroid treatment even if the patient was on high dose of
steroid), patients who were pregnant or nursing and had a
concomitant bacterial or fungal infection at the time of
hypoxia and/or in need for oxygen supplementation and the
patients receiving other antiinflammatory treatment such as
anticytokine therapies were excluded. In our institute,
COVID-19 was diagnosed through two different approaches.
First, the individuals with PCR positivity for SARS-CoV-2
were accepted as having microbiologically-documented
COVID-19. Moreover, the individuals with a negative PCR
test result were diagnosed with COVID-19 if they fulfilled all
three clinical criteria: (a) having fever and/or respiratory or
other symptoms of COVID-19, (b) having chest imaging
findings compatible with COVID-19 [14] and (c) having
decreased lymphocyte count while the white blood cell count
was normal or decreased. The treatment regimens for
COVID-19 were administered based upon the Turkish Health
Ministry COVID-19 Guidelines1. These guidelines have been
regularly revised and updated based upon scientific advances
achieved in COVID-19 treatment. Therefore, the patients’
treatment modalities may differ according to the currently
valid version of the guidelines at the time of the patient’s
COVID-19 diagnosis. In addition, requirement for ICU or
MV was decided by the ICU specialist by referring to the same
guidelines.
The aim of the study was to evaluate the efficacy of add-on
250 mg pulse methyl-prednisolone therapy in COVID-19
patients with inadequate response to high dose steroid (6
mg/day dexamethasone equivalent). Here, we compared this
treatment with two different treatment approaches. Herein,
we compared the efficacy of 250 mg pulse methylprednisolone therapy with standard care therapy and high
dose steroid treatment (6 mg/day dexamethasone equivalent)
plus standard therapy. Briefly, we compared three different
patient groups classified according to COVID-19 treatment
characteristics during hospitalization.
2.1. Treatment features of the study groups
The first group of patients received COVID-19 treatment in
the early phase of the pandemic. During this period, the
Turkish
Health
Ministry
COVID-19
Guidelines
recommended antiviral treatment (both favipravir and

hydroxychloroquine),
anticoagulation,
and
oxygen
supplement if necessary for COVID-19. In the initial version
of the guideline, corticosteroid treatment was not
recommended despite hypoxemia unless the patients had
another indication for corticosteroids. We categorized the
patients on these treatments in the standard care therapy
group.
The patients in the second group were diagnosed with
COVID-19 after the results of the RECOVERY trial were
announced [12]. At this point, the guideline
recommendations were revised to allow add- on
dexamethasone 6 mg/day or equivalent dose of any steroid
drug to the standard care therapy immediately after the
development of COVID-19 associated hypoxia and/or the
need for oxygen support. Here, the duration of the steroid
treatment was recommended as 10 days. Those patients
receiving dexamethasone plus standard care therapy were
classified as high dose steroid group.
Recently, the Turkish Health Ministry COVID-19
scientific committee recommended pulse steroid treatment
under the condition that the patients had inadequate response
to high dose steroid therapy. According to the latest
guidelines, no clinical, laboratory or radiological
improvement or deterioration of these findings after at least
three days of high dose steroid treatment may be indicative of
need for 250 mg of pulse steroid treatment. The
recommended treatment duration for pulse steroid therapy is
three days in a row. After pulse steroid treatment, the patients
are advised to keep up high dose maintenance steroid
treatment for a total of 10 days. Here, the patients who
received this therapy were classified as the pulse steroid group.
At this stage, all clinical, laboratory or radiological
assessments were performed based upon clinical judgment of
the physician. In both high dose and pulse steroid treatment
groups, the duration of the steroid treatments were decided
by the responsible physician according to clinical assessment
and laboratory findings. Therefore, the durations of the
steroid treatments may vary in accordance with the severity of
the patients’ clinical condition and physicians’ decision.
2.2. Patient enrolment methods and study parameters
The patients in all three groups were matched based upon age
(age of index case ± SD of pulse steroid group’s mean age),
sex, national early warning score-2 (NEWS) [15] at the onset
of hypoxia or in need of oxygen supplementation and
Charlson comorbidity index (CCI) [16]. The primary
outcomes of the study were mortality rate, the frequency of
MV or ICU requirement, length of hospital stay, length of stay
in ICU, and length of MV requirement and side effects related
to steroid treatments.
In this study, we have specified the patients in pulse
steroid group as the study cluster. First, we identified all
consecutive patients that were included in the pulse steroid
group in our institute’s COVID-19 cohort. Then, we matched
those patients with controls from other two groups (standard

1

Turkish Health Ministry. (2020). Guidance To Covid-19 (SARS Cov2 Infection) [Online]. Website: https://hsgm.saglik.gov.tr/tr/covid-19-ingilizce-dokumanlar.html [accessed 18/05/2020].
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care and high dose steroid groups). Here, we identified all
potential individuals in both control cohorts that might be
eligible to match the individual case in the pulse steroid group
based on age, sex, NEWS score at the onset of hypoxia and
CCI. Then, we randomly selected one of these patients from
the control cohorts respectively. Firstly, we numbered all
potential controls for individual case in study group
according to appointment date. Then, we selected one of them
with using a random-number generator2. Finally, we
compared the patients in pulse steroid group with both
control groups for primary outcome parameters.
We retrospectively collected the patient’s data from the
hospital’s medical database. Here, we have obtained the
demographic features of the patients (age, sex), comorbidities, presenting COVID-19 related symptoms, results
of SARS-CoV2 PCR test, treatment history for COVID-19
during hospitalization, requirement of intensive care unit,
requirement of mechanical ventilation, duration of
hospitalization, length of intensive care unit stay, laboratory
values at the onset of hypoxia (blood levels of biochemical
parameters including aspartate aminotransferase (AST),
alanine aminotransferase (ALT), creatinine, lactate
dehydrogenase (LDH), D-dimer, ferritin, C-reactive protein
(CRP), and hemograms), length of steroid treatments, steroid
related side effects, and outcome of the patients.
The levels of ALT, AST, creatinine, CK, LDH, albumin,
and CRP were classified according to the laboratory reference
ranges as normal, low, or high. However, ferritin and D-dimer
levels were classified based upon their levels related to
unfavourable prognosis in COVID-19. These cut-off levels
were specified as 300 mg/mL for ferritin and 1000 mg/L for
D-dimer [17]. Also, we focused on lymphocyte counts at
hemogram. Lymphocytes levels lower than 1 x 109/L were
accepted as cut-off value for severe disease. Moreover, NEWS
scores were classified as low (0–4), medium (5–6), and high
(≥7) [15]. Also, we have defined hypoxia if the oxygen
saturation of the patients is 93% or lower in room air3.
This study was approved by both the Local Research Ethics
Committee and the Turkish Health Ministry prior to data
collection and carried out in compliance with the Helsinki
Declaration.

for 28-day cumulative survival to standardize the study with
similar ones [18]. We used log-rank analysis to compare the
curves. We also evaluated the factors related to mortality in
pulse steroid group with multivariate analysis. The results
were given as inter-quartile range (IQR). A p-value lower than
0.05 was considered as statistically significant.
3. Results
3.1. Demographic features, baseline laboratory
values, and COVID-19 related symptoms
A total of 450 patients, equally distributed among the three
treatment groups were included in the study. Age, sex, disease
severity, and CCI scores were similar in all three groups.
SARS-CoV-2 PCR test positivity was more common in the
pulse steroid group compared to patients in the standard care
treatment group. Here, at least 4 of the 5 patients had PCR
positivity. Cough and shortness of breath was the most
common symptoms in all groups. Additionally, the frequency
of all evaluated co-morbid diseases was similar between the
groups. In the pulse steroid group, the frequency of patients
with baseline high transaminases, increased CRP or ferritin
levels, and decreased lymphocyte counts was found to be
more frequent than the standard care treatment group. In
addition, more patients in the high-dose steroid group had
increased transaminase levels and lower lymphocyte counts
compared to the standard care treatment group. All
demographic and laboratory values were similar between the
patients in high dose steroid and pulse steroid groups (Table
1).
3.2. COVID-19 treatment and outcome parameters
All patients in the study were hospitalized and had hypoxemia
or needed oxygen support at the time of enrolment. Pulse
steroid treatment was initiated after a median of 4.0 (2.0–6.0)
days after the start of need for oxygen support. Therefore, we
applied pulse steroid therapy due to unresponsiveness on the
fourth day of the high dose steroid treatment. In addition, the
duration of any dose previous steroid therapy was longer in
the pulse

2.3. Statistical analyses
Statistical analyses were carried out using SPSS v: 17.0 (SPSS
Inc., Chicago, IL, USA). In order to determine if the data were
normally distributed, the Kolmogorov–Smirnov test was
performed. None of the parameters distributed normally.
Therefore, comparisons of the continuous variables and
categorical variables were performed by Kruskal–Wallis and
Chi-square test, respectively. Then, we conducted post-hoc
analysis with Bonferonni adjusted Mann–Whitney U or chisquare tests if necessary. Kaplan–Meier survival curves were
used to show 28-day cumulative survival after the onset of
target treatment or hypoxia. Here, we compared the groups
2

Research Randomizer (Version 4.0) (2013). Website: http://www.randomizer.org/. [accessed: 22/06/ 2013].
Turkish Health Ministry. (2020). Guidance To Covid-19 (SARS Cov2 Infection) [Online]. Website: https://hsgm.saglik.gov.tr/tr/covid-19-ingilizce-dokumanlar.html [accessed 18/05/2020].
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Table 1. Demographic and disease-related features of the COVID-19 patients.
Standard care
High steroid treatment
treatment
n = 150+
n = 150*
Age (year)
60.0(48.7–71.0) 59.5(49.0–71.2)

Pulse steroid treatment
n =150¶

Post-hoc analyses

p

59.5(48.0-70.7)

NS

0.98

Sex (M/F)

100/50

100/50

100/50

NS

N/A

Positive PCR test result, n(%)

122(81.3)*

133(88.7)

141(94.0)*

*p < 0.001

0.03

Disease severity (NEWS-2 score)*

6.0(2.0-7.0)

6.0(4.0-7.0)

6.0(4.0-7.2)

NS

0.22

Low

39 (26.0)

39 (26.0)

39 (26.0)

Moderate

48(32.0)

48(32.0)

48(32.0)

High

63(42.0)

63(42.0)

63(42.0)

Cough

93(62.0)

95(63.3)

95(63.3)

NS

0.94

Shortness of breath

66(44.0)*

91(60.7)

113(75.3)*

* p < 0.001

<0.001

Fever

75(50.0)

55(36.7)

60(40.0)

NS

0.05

¶

Presenting symptoms n(%)

¶

¶

Myalgia

27(18.0)*

29(19.3)

47(31.3)*

* p < 0.001

0.01

Headache

11(7.3)

11(7.3)

12(8.0)

NS

0.96

Sore throat

10(6.7)

7(4.7)

7(4.7)

NS

0.68

Loss of taste or smell

11(7.3)

12(8.0)

11(7.3)

NS

0.16

Malaise

47(31.3)*

56(37.3)

74(49.3)*

* p = 0.001

0.005

Diarrhoea

7(4.7)

14(9.3)

8(5.3)

NS

0.22

Nausea/vomiting

13(8.7)

25(16.7)

11(7.3)

NS

0.05

Loss of appetite

10(6.7)

16(10.7)

18(12.0)

NS

0.25

Charlson comorbidity index score

3(1–4)

3(1–4)

3(1–4)

NS

0.80

Diabetes mellitus

53(35.3)

46(30.7)

62(41.3)

NS

0.15

Hypertension

66(44.0)

61(40.7)

69(46.0)

NS

0.64

Coronary arterial disease

34(22.7)

30(20.0)

27(18.0)

NS

0.60

COPD

8(5.3)

9(6.0)

8(5.3)

NS

0.95

Asthma

14(9.3)

12(8.0)

7(4.7)

NS

0.25

Malignancy

6(4.0)

16(10.7)

14(9.3)

NS

0.06

Chronic renal disease

7(4.7)

8(5.3)

10(6.7)

NS

0.74

Rheumatic diseases

5(3.3)

3(2.0)

4(2.7)

NS

0.77

Transaminases (>35 IU/L)

36(24.0)*

70(46.7)¶

64(42.7)*¶

Creatinine (>1.2 mg/dL)

25(16.7)

37(24.7)

33(22.0)

*p < 0.001
¶
p = 0.001
NS

LDH ( >240 U/L)

89(59.3)*

104(69.3)

122(81.3)*

*p < 0.001

0.01

D-dimer (≥1000 ng/mL)

53(35.3)

72(48.0)

79(52.7)

0.23

Lymphocyte count (≤1x109/L)

47(31.3)*¶

76(50.7)¶

89(59.3)*

Ferritin ( ≥300 mg/mL)

36(24.0)*

94(62.7)

117(78.0)*

NS
*p = 0.001
¶
p < 0.001
*p < 0.001

CRP (>10 mg/dL)

123(82.0)*

138(92.0)

145(96.7)*

*p < 0.001

<0.001

Co-morbidities n(%)

Laboratory findings*

steroid group (p = 0.01). The antiviral treatment approach
was different between standard care therapy group compared
to steroid therapy groups related to the currently available
versions of our national guidelines. More patients in the
standard care treatment group received hydroxychloroquine,
antibiotics, and lopinavir-ritonavir than the patients in the

<0.001
0.20

<0.001
<0.001

other two groups. However, none of the patients in our
standard care therapy group received any dose of steroid.
Also, favipravir was the most preferred antiviral treatment
agent in the steroid therapy groups. There was no difference
between the groups according to anticoagulant therapy (Table
2).
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Mortality rates were similar in all groups. However, there
was a trend for lower mortality rates in both steroid groups.
Both ICU or MV requirement rates were lower in the high
steroid dose group compared to standard care and pulse
steroid therapy groups (p = 0.03 and p = 0.02, respectively).
Also, the length of hospitalization was significantly different
in all groups. Duration of hospital stay was the shortest in the
high dose steroid group [8.0 (5.5–12.2) days]. In addition, the
length of stay in ICU was the shortest in the pulse steroid
group although the difference was significant only between
standard care and pulse steroid groups (p = 0.01) (Table 2).
Median duration of ICU stays were 9.0 (CI 95% 6.0–12.0) days
in standard care group, 8.0 (CI 95% 5.0–13.0) days in high
dose steroid group and finally 4.5 (CI %95 3.0–8.0) days in
pulse steroid group.
Steroid- related side effects were more common in the
pulse steroid treatment group (p = 0.03). However, less than
5% of the patients had steroid-related side effects in both
groups. The most common side effect was increased blood
sugar levels. Four patients from pulse steroid group and one
patient from high dose steroid group had increased blood

and one patient from high dose steroid group had dyspeptic
complaints. None of the patients had steroid therapy related
bacterial or fungal infections. Additionally, none of the
patients’ steroid treatment was terminated due to any side
effect.
In the severe COVID-19 patients (NEWS-2 score >6),
both ICU and MV requirements were lower in steroid
treatment groups than in standard care group (p = 0.03 and p
= 0.008, respectively). Length of hospitalization was also the
shortest in high dose steroid treatment group. In addition, the
length of stay in ICU was the shortest in the pulse steroid
treatment group although the difference was significant only
between standard care and pulse steroid treatment groups (p
= 0.03) (Table 3).
We performed an analysis of 28-day survival after the
initiation of the target therapy or development of hypoxia.
There was no difference between the survival curves of the
groups (p = 0.36). However, after the fifteenth day, survival
curves differentiated between the standard care treatment and
steroid treatment groups. At this point, fewer patients died in
the steroid groups compared to standard care treatment

Table 2. Disease-related features, treatment properties, and outcomes of the COVID-19 patients.
Standard care High dose steroid
treatment
treatment
n = 150
n = 150
Time from onset of symptoms to oxygen
¶
4.0 (2.0–7.0)* 7.0 (3.0–9.5)¶
supplementation (days)
Time from onset of oxygen supplementation to pulse
N/A
N/A
steroid treatment (days)
Time from onset of oxygen supplementation to ICU
5.0 (3.0–6.0)* 4.0 (3.0–7.0)¶
requirement (days)
Duration of total steroid treatment (days)
N/A
6.0 (4.0–9.0)
Duration of pulse steroid dose treatment (days)

N/A

N/A

Pulse steroid
treatment
n = 150

Post-hoc
analyses

p

7.0 (4.0–10.0)*

*¶p < 0.001

<0.001

4.0 (2.0–6.0)
2.0 (1.0–3.5)*¶

N/A
*¶p = 0.01

0.01

7.0 (5.0–9.0)

0.01

3.0 (3.0–3.0)

N/A

Treatment, n(%)
Hydroxychloroquine
Favipravir

144(96.0)*¶
¶

43(28.7)¶
¶

67(44.7)*

132(88.0)
¶

¶

64(42.7)*

*¶p < 0.001

<0.001

141(94.0)*

*¶p < 0.001

<0.001

¶

Antibiotics

127(84.7)*

51(34.0)

48(32.0)*

* p < 0.001

<0.001

Remdesivir

0(0)

14(9.3)

7(4.7)

NS

<0.001

Lopinavir–Ritonavir

12(8.0)

0(0)

0(0)

N/A

Anticoagulant treatment

136(90.6)

144(96.0)

146(97.3)

0.21

Deceased

24(16.0)

16(10.7)

14(9.3)

NS

Discharged

126(84.0)

134(89.3)

36(90.7)

NS

Requirement of ICU

32(21.3)*

17(11.3)*

20(13.3)

*p = 0.01

0.03

Requirement of MV

16(10.7)

*p = 0.01

0.02

12.0 (9.0–15.0)*¶

*¶+p < 0.001

<0.001

Length of ICU stay (days)

28(18.7)*
13(8.7)*
10.0 (6.0–
7.0 (5.0–11.0)¶+
14.0)*+
9.0 (5.7–13.0)* 8.0 (5.5–12.2)

4.5 (2.2–8.0)*

*p = 0.01

0.03

Length of MV (days)

7.5 (3.5–11.0) 6.5 (3.2–8.7)

3.5 (2.0–7.7)

0.13

6(4.0)

0.03

Primary endpoints n(%)

Length of hospitalization (days)

Steroid side effects
N/A
2(1.3)
ICU: intensive care unit; MV: mechanical ventilation. *At the time of the onset of hypoxia
p < 0.05 was shown bold. NS: nonsignificant. p < 0.017 was shown in post-hoc analysis
Comparisons in post-hoc analyses with p value < 0.017 was shown in the table.

sugar levels. Moreover, two patients receiving pulse steroid
2252

group (Figure).

0.17

BATIREL et al. / Turk J Med Sci

Table 3. Primary endpoints in patients with severe COVID-19 (NEWS-2 score > 6).
Standard care
High dose steroid Pulse steroid
treatment
treatment
treatment
n = 63
n = 63
n = 63
Primary endpoints n(%)

Post-hoc analyses

P

0.06

Deceased

15(23.8)

11(17.4)

5(7.9)

Requirement of ICU

21(33.3)*¶

12(19.0)¶

9(14.3)*

Requirement of MV

20(31.7)*¶

10(15.8)¶

6(9.5)*

Length of hospitalization (days)

11.5 (7.0–16.0)*

7.0 (4.7–12.0)*¶

12.0 (8.0–15.0)¶

NS
*p = 0.001
¶
p = 0.01
*p = 0.001
¶
p = 0.01
*¶p < 0.001

Length of ICU stay (days)

10.0 (7.0–25.0)*

7.0 (5.0–13.0)

3.0 (2.0–7.0)*

*p = 0.01

0.03

NS

0.21

Length of MV (days)
8.0 (5.2–15.7)
7.0 (3.5–9.0)
4.0 (1.7–8.7)
ICU: intensive care unit; MV: mechanical ventilation. *At the time of the onset of hypoxia
p < 0.05 was shown bold. NS: nonsignificant p < 0.017 was shown in post-hoc analysis.

Lastly, we conducted multivariate analyses to evaluate the
features related to mortality in pulse steroid group. Only
creatinine level higher than 1.2 mg/dL was found to be related
to mortality in study group (Table 4).
4. Discussion
In this study, in which we evaluated the effectiveness of addon 250 mg pulse methyl-prednisolone treatment in addition
to high dose steroid treatment (6 mg/day dexamethasone
equivalent) in case of unresponsiveness, the pulse steroid
group had shorter ICU stay as compared to the other groups.
Additionally, patients in the pulse steroid group achieved
similar results in other outcome parameters except the total
length of hospital stay.
After the RECOVERY trial results were published [12],
high dose steroid therapy in an equivalent dose of 6 mg
dexamethasone became a treatment option for COVID-19
patients. In the original paper, the therapy had beneficial
effect only on the patients who needed oxygen support. As
expected, some patients in this study did not respond to high
dose steroid therapy. In this case, administration of higher
steroid dose would be a treatment option. There are
controversial reports about the efficacy of pulse steroid
therapy. Some recently published papers have shown the
favorable effects of higher steroid doses in COVID-19 patients
with pulmonary involvement [19–21]. In these studies,
effectiveness of pulse steroid treatment was compared to
standard care therapy only without any prior steroid
administration. Here, there were significantly better outcome
parameters in the results of the pulse steroid groups. In one
study, very high dose steroid treatment increased ventilatorfree days [21] while in others, this treatment was associated
with higher survival rates. In contrary, another study found
that pulse steroid therapy was associated with increased
mortality compared to standard care therapy, especially in
older adults [22]. Our study was unique because we evaluated
the effectiveness of pulse steroid treatment on outcome
parameters by comparing the two other groups (standard care
and high dose steroid groups) for the first time in the
literature. In addition, according to our study protocol, we
primarily focused on the effects of add-on pulse steroid

0.03
0.008
<0.001

Table 4. Multivariate analyses for mortality in pulse steroid
group.
OR
%95 CI
P
Male sex
3.11
0.70–14.3
0.13
Age
0.94
0.89–1.02
0.05
Charlson comorbidity
0.96
0.70–1.32
0.88
index score
NEWS-2 score*
0.97
0.74–1.28
0.86
Creatinine (>1.2 mg/dL)
8.9*
2.3–34.6*
0.002*
NEWS-2: national early warning score-2, *At the time of the onset
of hypoxia. Regression analyses include the variables significantly
related to mortality in univariate analyses (age, Charlson
comorbidity index score, creatinine (>1.2 mg/dL)), NEWS-2
score and sex
*p < 0.05.

treatment on COVID-19 patients who did not respond to
high dose steroid therapy.
All groups in our study were matched based upon age, sex,
disease severity at the onset of hypoxia, and weight of comorbidities. However, there were some differences between
the groups due to the phase of the pandemic in our country
when the patients were selected. First of all, the standard care
treatment group was included in the first phase of the
pandemic. At this phase, these patients did not receive any
steroid therapy and antiviral therapy options were different
from the subsequent phases of the outbreak. However, since
the host immune response is the main pathophysiological
mechanisms for the disease [23], these patients did not receive
adequate immune modulation therapy. Additionally, the
second group of our study was similar to the dexamethasone
group of the RECOVERY trial. Finally, pulse steroid group
had some important characteristics that influenced the results
of the study. Firstly, these patients were nonresponders of
high dose steroid treatment group. Although baseline clinical
and demographic features of the patients were similar with the
other groups, they did not respond to at least 3 days of high
dose steroid treatment. Therefore, those patients would have
clinically more severe disease. Also, without pulse steroid
treatment, they would likely have negative outcomes.
According to our results, patients in the pulse steroid
group had similar results to the high-dose steroid group, with
shorter ICU stays but longer hospital stays. Since those
2253
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Figure. 28-day cumulative survival graphic of the patients in the 3 study groups.

patients had clinically more severe disease, longer treatment
duration is expected. However, increasing steroid dose has a
beneficial effect with suppressing the host inflammation more
efficiently and controlling the severity of the disease with
shorter ICU stays. Although not statistically significant, the
number of ventilator-free days was also more increased in
pulse steroid group than the others. Therefore, we compared
high dose steroid group which included both steroid
responders and nonresponders, with those who did not
respond to this treatment alone. Here, pulse steroid therapy
can prevent worse outcomes in these patients.
The mortality rate was similar among the groups.
However, standard care treatment group patients had
nonsignificantly higher rate of mortality. Furthermore, after
the fifteenth day of the treatment or hypoxia, survival curves
in both steroid groups flattened compared to standard care
group. Also, pulse steroid therapy probably would reduce the
mortality rate of the high dose steroid treatment
nonresponders.
The high dose steroid treatments have several side effects
[24]. In our cohort, less than 5% of the patients in steroid
treatment groups had steroid-related side effects. In addition,
no patient’s steroid treatment was discontinued due to these
2254

side effects. Here, the most common side effect was increased
blood sugar levels. Furthermore, a study showed that there
was no increase in hospital mortality due to any secondary
infection in the patients receiving high dose steroid for the
treatment of COVID-19 [25]. Therefore, we thought that
under these specific conditions, high or very high steroid dose
could be tolerated.
Our study has some limitations. First of all, our study is a
retrospective controlled study. Although we matched the
groups according to several parameters, it is not a randomized
controlled study. Additionally, we enrolled the controls from
the different stages/phases of the pandemic. Therefore, there
were some differences in treatment approaches, especially in
the antiviral therapy. Finally, the pulse steroid therapy group
would be considered as the more severe form of the higher
dose steroid treatment groups, although the groups were also
matched in terms of initial disease severity.
In conclusion, pulse steroid treatment would decrease the
length of ICU stays and probably may have beneficial effect
on outcomes in the nonresponder patients of high dose
steroid treatment without significant side effects. Therefore,
pulse steroid treatment would be a tolerable treatment
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approach for the treatment of the COVID-19 patients who do
not respond to the initial high dose steroid treatment.
Informed consent
None.
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